Literature DB >> 16617003

Quantitative prognostic indices in peritoneal carcinomatosis.

F N Gilly1, E Cotte, C Brigand, O Monneuse, A C Beaujard, G Freyer, O Glehen.   

Abstract

Five different descriptions quantitating peritoneal carcinomatosis are available: the Lyon staging system, the Peritoneal Cancer Index (PCI), the Japanese Research Society for Gastric Cancer carcinomatosis staging (JRSGS), the Dutch simplified peritoneal carcinomatosis assessment and the Completeness of Cytoreduction Score (CCR). These five staging systems are described and discussed. Combinations of these to achieve a complete description of peritoneal lesions prior to and following treatment assist in a correct prognostic assessment for these patients and in a selection of treatment options.

Entities:  

Mesh:

Year:  2006        PMID: 16617003     DOI: 10.1016/j.ejso.2006.03.002

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  23 in total

1.  Concordance of laparoscopic and laparotomic peritoneal cancer index using a two-step surgical protocol to select patients for cytoreductive surgery in advanced ovarian cancer.

Authors:  Martina Aida Angeles; Federico Migliorelli; Mathilde Del; Carlos Martínez-Gómez; Manon Daix; Sarah Bétrian; Erwan Gabiache; Gisèle Balagué; Sophie Leclerc; Eliane Mery; Laurence Gladieff; Gwénaël Ferron; Alejandra Martinez
Journal:  Arch Gynecol Obstet       Date:  2021-01-03       Impact factor: 2.344

Review 2.  Pseudomyxoma Peritonei: Case Report and Literature Review.

Authors:  Keishla M García; Karla M Flores; Alejandro Ruiz; Frances L González; Ángel M Rodríguez
Journal:  J Gastrointest Cancer       Date:  2019-12

3.  The development of a peritoneal surface malignancy program: a tale of three hospitals.

Authors:  Umut Sarpel; Marcovalerio Melis; Elliot Newman; H Leon Pachter; Russell S Berman
Journal:  J Cancer Educ       Date:  2012-12       Impact factor: 2.037

4.  FDG-PET/ceCT is useful to predict recurrence of Pseudomyxoma peritonei.

Authors:  Julien Dubreuil; Francesco Giammarile; Pascal Rousset; Naoual Bakrin; Guillaume Passot; Sylvie Isaac; Olivier Glehen; Andrea Skanjeti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-02-24       Impact factor: 9.236

Review 5.  Abdominal metastases from colorectal cancer: intraperitoneal therapy.

Authors:  Hamza Guend; Sunil Patel; Garrett M Nash
Journal:  J Gastrointest Oncol       Date:  2015-12

6.  Identifying the incidence of respiratory complications following diaphragmatic cytoreduction and hyperthermic intraoperative intraperitoneal chemotherapy.

Authors:  P Cascales Campos; L A Martinez Insfran; D Wallace; J Gil; E Gil; A Gonzalez Gil; J Martínez; J L Alonso Romero; R Gonzalez Sanchez; P Parrilla
Journal:  Clin Transl Oncol       Date:  2019-08-07       Impact factor: 3.405

7.  Correlation of Radiologic with Surgical Peritoneal Cancer Index Scores in Patients with Pseudomyxoma Peritonei and Peritoneal Carcinomatosis: How Well Can We Predict Resectability?

Authors:  Kristina Flicek; Awais Ashfaq; C Dan Johnson; Christine Menias; Sanjay Bagaria; Nabil Wasif
Journal:  J Gastrointest Surg       Date:  2015-07-11       Impact factor: 3.452

8.  Impact of a modified peritoneal cancer index using FDG-PET/CT (PET-PCI) in predicting tumor grade and progression-free survival in patients with pseudomyxoma peritonei.

Authors:  Masatoshi Hotta; Ryogo Minamimoto; Yoshimasa Gohda; Toru Igari; Hideaki Yano
Journal:  Eur Radiol       Date:  2019-03-14       Impact factor: 5.315

Review 9.  Diagnostic Laparoscopy in the Pre-operative Assessment of Patients Undergoing Cytoreductive Surgery and HIPEC for Peritoneal Surface Malignancies.

Authors:  Ramakrishnan Ayloor Seshadri
Journal:  Indian J Surg Oncol       Date:  2016-01-11

10.  Evaluation of repeat cytoreductive surgery and heated intraperitoneal chemotherapy for patients with recurrent peritoneal carcinomatosis from appendiceal and colorectal cancers: a multicentre Canadian study

Authors:  Evan Jost; Lloyd A. Mack; Lucas Sideris; Pierre Dube; Walley Temple; Antoine Bouchard-Fortier
Journal:  Can J Surg       Date:  2020-02-21       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.